MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from common
stock subscribed
$5,228K
Net cash provided by
financing activities
$5,225K
Effects of exchange rate
changes on cash and cash...
$12K
Canceled cashflow
$3K
Net increase
(decrease) in cash and cash...
$495K
Canceled cashflow
$4,742K
Repayment of long-term
loan
$3K
Common stock-based
compensation and expenses,...
$2,108K
Depreciation and
amortization
$324K
Deposits and advances
-$195K
Accounts payable
$132K
Operating lease asset
-$87K
Inventory
-$36K
Accounts receivable, net
-$22K
Claims and advances
-$11K
Sale of property,
plant, and equipment
$681K
Net cash used in
operating activities
-$4,720K
Net cash from (used)
in investing...
-$22K
Canceled cashflow
$2,915K
Canceled cashflow
$681K
Net loss
-$4,146K
Other non-cash items
-$3,234K
Acquisition and development
of intangible...
$604K
Accrued and other
liabilities
-$248K
Operating lease liability
-$7K
Investment in short-term
investments
$50K
Purchase of property,
plant, and equipment
$49K
Back
Back
Cash Flow
source: myfinsight.com
IGC Pharma, Inc. (IGC)
IGC Pharma, Inc. (IGC)